Detalhe da pesquisa
1.
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
Proc Natl Acad Sci U S A
; 121(15): e2322563121, 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38557192
2.
Clinically relevant humanized mouse models of metastatic prostate cancer facilitate therapeutic evaluation.
Mol Cancer Res
; 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38820127
3.
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
bioRxiv
; 2024 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38464081
4.
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
bioRxiv
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38586029
5.
Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies.
bioRxiv
; 2024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38328238
6.
Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.
Crit Rev Oncol Hematol
; 157: 103186, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33309571
7.
Retinal Nerve Fibre Layer Thinning in Patients with Thalassaemia, Iron Deficiency Anaemia, and Anaemia of Chronic Diseases.
J Ophthalmol
; 2020: 9268364, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33282416